Latest Health News

Respiri Limited has completed its acquisition of Orb Health Inc. for US$9 million in shares, marking a strategic move to strengthen its foothold in the US connected and chronic care market. The integration promises operational cost savings and expanded service offerings.

Wesfarmers has announced the wind down of Catch as a standalone business, transferring its e-commerce fulfilment centres to Kmart Group and integrating key digital capabilities into its retail divisions to strengthen omnichannel offerings.

Korvest Ltd has announced a fully franked ordinary dividend of AUD 0.25 per share for the six months ending December 2024, signaling steady shareholder returns.

Immuron Limited reports a striking 70% quarter-on-quarter increase in Travelan® sales, driven by expanded pharmacy distribution in Australia and North America.

Visioneering Technologies reports promising interim results from its PROTECT trial, showing significant control of myopia progression in children using NaturalVue® Multifocal lenses.

Pro Medicus has secured a $33 million, nine-year contract to implement its Visage 7 cloud-based imaging platform across the University of Kentucky’s health system, marking a significant expansion in North American academic healthcare.

Memphasys Limited has secured a major scientific endorsement for its RoXsta™ antioxidant profiling system, positioning the technology for expanded clinical and agricultural applications.

Genesis Minerals Limited reported a record December quarter gold production of 57,055oz, driven by an accelerated Laverton mill restart and strong operational execution. The company’s cash reserves surged 34% to A$238 million, underpinning its debt-free growth strategy.

Orthocell Limited has reported a third consecutive quarter of record revenue, driven by strong sales growth and strategic market expansions, including a key US FDA submission for its nerve repair product Remplir™.

Anatara Lifesciences has successfully completed recruitment for the second stage of its pivotal GaRP-IBS clinical trial, with headline results expected in Q1 2025. The company also launched a new anti-obesity project and strengthened its cash position through recent capital raises.

HITIQ Limited has received $1.6 million from the R&D Tax Incentive Scheme, using most of it to repay its RDTI Facility with Keystone Capital Partners, signaling a strategic move to streamline its R&D funding.

Immuron has submitted its Phase 2 clinical study report for Travelan® to the FDA, revealing statistically significant immunological and microbiome benefits. The company is preparing to engage the FDA for Phase 3 trial discussions while progressing a large field study with military personnel.